Zacks: Analysts Expect Uniqure NV (NASDAQ:QURE) Will Announce Earnings of -$0.89 Per Share

Share on StockTwits

Wall Street brokerages forecast that Uniqure NV (NASDAQ:QURE) will report earnings of ($0.48) per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Uniqure’s earnings, with the lowest EPS estimate coming in at ($1.18) and the highest estimate coming in at ($0.72). Uniqure reported earnings per share of ($0.83) during the same quarter last year, which would suggest a positive year-over-year growth rate of 42.2%. The company is expected to issue its next quarterly earnings report on Monday, August 3rd.

On average, analysts expect that Uniqure will report full-year earnings of ($0.03) per share for the current fiscal year, with EPS estimates ranging from ($3.19) to $7.26. For the next year, analysts anticipate that the firm will report earnings of ($0.99) per share, with EPS estimates ranging from ($3.80) to $1.53. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Uniqure.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.21. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.76 million. Uniqure had a negative return on equity of 45.23% and a negative net margin of 1,991.17%.

QURE has been the topic of several research analyst reports. Robert W. Baird cut Uniqure from an “outperform” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a research report on Thursday, June 25th. ValuEngine lowered Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 14th. Stifel Nicolaus reduced their price objective on Uniqure from $86.00 to $78.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. They noted that the move was a valuation call. Wells Fargo & Co cut Uniqure from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $90.00 to $56.00 in a report on Thursday, June 25th. Finally, HC Wainwright dropped their target price on Uniqure from $73.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, June 25th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $74.00.

In related news, insider Robert Gut sold 26,875 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $70.00, for a total transaction of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 9,376 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $56.87, for a total value of $533,213.12. Following the transaction, the chief executive officer now directly owns 327,918 shares of the company’s stock, valued at approximately $18,648,696.66. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,002 shares of company stock valued at $3,044,829. 2.66% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the business. RMR Wealth Builders bought a new stake in shares of Uniqure in the 4th quarter worth $89,000. Bamco Inc. NY grew its holdings in shares of Uniqure by 34.2% in the fourth quarter. Bamco Inc. NY now owns 1,570 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 400 shares during the period. Sowell Financial Services LLC grew its holdings in shares of Uniqure by 451.2% in the first quarter. Sowell Financial Services LLC now owns 1,874 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 1,534 shares during the period. Sofos Investments Inc. grew its holdings in shares of Uniqure by 18.9% in the fourth quarter. Sofos Investments Inc. now owns 1,939 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 308 shares during the period. Finally, Brinker Capital Inc. bought a new stake in shares of Uniqure in the fourth quarter worth $206,000. 78.65% of the stock is owned by institutional investors and hedge funds.

NASDAQ QURE opened at $45.73 on Friday. The business has a 50 day moving average price of $61.36 and a 200-day moving average price of $59.87. Uniqure has a 52 week low of $36.20 and a 52 week high of $77.46. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.89 and a current ratio of 12.89.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Article: Marijuana Stocks Investing Considerations

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Two Sigma Advisers LP Grows Stock Position in Argo Group
Two Sigma Advisers LP Grows Stock Position in Argo Group
Systemax  Lowered to Hold at Zacks Investment Research
Systemax Lowered to Hold at Zacks Investment Research
Stepan  Upgraded to “Hold” at Zacks Investment Research
Stepan Upgraded to “Hold” at Zacks Investment Research
Limelight Networks, Inc.  Insider Michael Disanto Sells 24,282 Shares
Limelight Networks, Inc. Insider Michael Disanto Sells 24,282 Shares
Cenovus Energy Inc  Stock Holdings Lifted by Morgan Stanley
Cenovus Energy Inc Stock Holdings Lifted by Morgan Stanley
Hall Kathryn A. Purchases New Holdings in Microsoft Co.
Hall Kathryn A. Purchases New Holdings in Microsoft Co.


© 2006-2020 Ticker Report